BRIEF-Neurocrine announces FDA conditional acceptance of Ingrezza
August 31, 2016 at 16:23 PM EDT
* Neurocrine announces FDA conditional acceptance of proprietary name Ingrezza for VMAT2 inhibitor valbenazine
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.